Suchergebnisse - "Cook, Gordon"

PubPharm (6)

1

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma : a consensus report of the European Myeloma Network

enthalten in: The Lancet. Oncology | 2023

von Ludwig, H. | Terpos, E. | van de Donk, N. | +26

2

Treatment of relapsed and refractory multiple myeloma : recommendations from the International Myeloma Working Group

enthalten in: The Lancet. Oncology | 2021

von Moreau, P. | Kumar, S. | San Miguel, J. | +67

3

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Jackson, G. | Davies, F. | Pawlyn, C. | +19

CommentIn: Lancet Oncol. 2019 Jan;20(1):5-6. - PMID 30559052

4

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2014

von Cook, G. | Williams, C. | Brown, J. | +15

ErratumIn: Lancet Oncol. 2014 Aug;15(9):e365 Dosage error in article text

5

Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation : a retrospective study

enthalten in: The Lancet. Oncology | 2012

von Fleischhauer, K. | Shaw, B. | Gooley, T. | +101

ErratumIn: Lancet Oncol. 2012 Apr;13(4):e134-5

6

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX) : secondary outcomes from a randomised controlled trial

enthalten in: The Lancet. Oncology | 2011

von Morgan, G. | Child, J. | Gregory, W. | +17

CommentIn: Lancet Oncol. 2011 Aug;12(8):711-2. - PMID 21771569

1
[1]